MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Clinical trial NCT03962543 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03962543
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-29
- Primary completion
- 2023-09-20
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.